Clinician-supervised GLP-1 support

The lifestyle layer that makes GLP-1 therapy work

Better adherence, preserved muscle and a supported off-ramp, with clinician sign-off and outcomes reported back to the payer.

Adherence Muscle preservation Side-effect support Structured off-ramp
The problem

Payers are spending heavily on GLP-1s and not keeping the results

1 in 12

members remain on GLP-1 treatment after three years

77%

of large US employers rate managing GLP-1 costs as extremely or very important

Regain

after stopping, plus lean-muscle loss during treatment, with little structured support

Sources: Prime Therapeutics data, cited by Mercer, “GLP-1 considerations for 2026”; Mercer employer survey.

Why now

As drug prices fall, value moves to the program around the drug

Prices are falling

US agreements cut GLP-1 prices from over $1,000 to as low as $245 a month for eligible patients, and oral options are arriving.

Payers want lifestyle support

Employers and plans increasingly tie coverage to lifestyle and behavioral programs.

Medicare is paying for outcomes

The CMS ACCESS Model pays for technology-enabled care tied to outcomes in chronic conditions.

Sources: IQVIA, “Outlook for Obesity in 2026”; MedCity News, Jan 2026; AAMC on the CMS ACCESS Model.

The program

One program across the whole GLP-1 journey

1 · Start

Baseline and onboarding

Body composition, activity, nutrition and gut-health baseline, plus a side-effect plan.

2 · Maintain

Adherence and muscle

Protein and strength targets, GI side-effect support and early flags for drop-off.

3 · Off-ramp

Supported step-down

A structured taper with the prescriber, and habits that hold results.

Activity comes from a wearable, the phone or a weekly check-in; nutrition and gut guidance from LIWEL’s own nutrition engine. A licensed clinician reviews and signs off every plan change. Prescribing stays with the member’s own clinician.

Outcomes

The payer sees what its GLP-1 spend is buying

OutcomeWhat we measureWhy the payer cares
AdherenceMonths on therapy; drop-off flags acted onValue from each fill
Muscle preservationLean-mass trend, strength and activityHealthier weight loss
Side effectsGI symptoms logged and resolvedFewer early stops
Off-rampWeight held after step-downLower long-term drug cost

Reported per cohort to the employer or plan, de-identified, each quarter. Outcome definitions and targets are agreed with each buyer.

How we work with payers

Paid per member, with part of the fee tied to outcomes

First

Self-insured employers

A per-member-per-month fee, with a share at risk on adherence and outcomes.

Next

Health plans, PBMs and obesity practices

The program as a condition of coverage, or white-labeled for prescribers.

Later

Medicare and cash-pay members

Outcome-based Medicare models, and direct subscriptions.

What sets LIWEL apart

We measure what keeps the results

Measured muscle preservation

Lean mass and strength are tracked, not just the scale.

Gut and side-effect support

Gut-health data and nutrition guidance help keep members on therapy.

A structured off-ramp

Step-down with the prescriber, monitored afterwards.

Clinician sign-off, one record

With or without a wearable: one record, and every change approved.

The platform

Signal, not noise, with or without a wearable

1

Ingest

Wearable, phone or check-in, meal logs and gut data.

2

Quality gate

Each source is scored for confidence; noise and gaps are dropped.

3

Personal baseline

Each member is compared to their own recent norm.

4

Fuse

Our nutrition engine, GI symptoms, weight and dose adherence.

5

Flag

Versioned rules give a plain-language flag and its reason.

6

Sign off, then learn

A clinician approves; outcomes tune the rules.

Three data tiers, one program

No device: meal logs, a weekly check-in, weight and clinic body composition. A phone adds steps; a wearable adds heart rate and sleep. Same flags, rising confidence.

No device+ Phone+ Wearable
Example flag · drop-off risk

Protein below target on 5 of 7 days, GI score up 2+ points and activity 30%+ below the member’s own baseline → a clinician reviews, with reasons and confidence.

Example thresholds are illustrative and are set and validated by our clinical team.

Building the evidence

Two tracks to evidence in 2027

US · GLP-1 pilot

Employer pilot

A planned six-month pilot with a self-insured employer, for members on GLP-1 therapy.

US · IRB research study

Randomized study

Standard care vs LIWEL, with lean mass measured by DEXA, testing early-signal hypotheses.

Adherence at 3 and 6 months Lean-mass trend Side-effect resolution Member experience Reported by data tier

Planned pilot readouts. LIWEL does not yet have US outcome results.

Team

The people behind LIWEL

Neela

Founder & CEO

Serial founder with 20+ years of GCC leadership at Cisco, Juniper and Epicor.

Pankaja Shankar

Co-founder & CTO

Leads the core AI and predictive engine.

Giri Chenji

Clinical & Regulatory

Former CTO, Immuneel; Deloitte Health (US).

Dr. Chithra Ram

Co-founder · Clinical

Neuroradiologist with a fellowship in neuroradiology at Duke.

Obesity medicine advisorWe’re seeking a US obesity-medicine physician.
Platform ArchitectNow hiring.
Work with us

Let’s design a GLP-1 pilot together

We’re talking with self-insured employers and benefits consultants, obesity-medicine physicians, and health plans and PBMs.

Employers Benefits consultants Physicians Health plans & PBMs
neela.kishore@liwel.health